key: cord-0759365-qbnjn95n
authors: Ghosh, Prakash; Chowdhury, Rajashree; Hossain, Mohammad Enayet; Hossain, Faria; Miah, Mojnu; Rashid, Md. Utba; Baker, James; Rahman, Mohammed Ziaur; Rahman, Mustafizur; Ma, Xuejun; Duthie, Malcolm S.; Wahed, Ahmed Abd El; Mondal, Dinesh
title: Evaluation of recombinase-based isothermal amplification assays for point-of-need detection of SARS-CoV-2 in resource-limited settings
date: 2021-11-07
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.11.007
sha: d5c150f51695dd2b973aa9f4508b1dfc66683cce
doc_id: 759365
cord_uid: qbnjn95n

Objectives Democratization of diagnostics is one of the key challenges towards harnessing the transmission of COVID-19 around the globe. The operational complexities of existing PCR-based methods, including sample transfer to advanced central laboratories with expensive equipment, limit their use in resource-limited settings. However, with the advent of the isothermal technologies, detection of SARS-CoV-2 is possible at decentralized facilities. Methods In this current study, two recombinase-based isothermal techniques, reverse transcription recombinase polymerase amplification assay (RT-RPA) and reverse transcription recombinase aided amplification assay (RT-RAA), were evaluated for detection of SARS-CoV-2 in clinical samples. In total,76 real-time reverse transcription polymerase chain reaction (real-time RT-PCR) confirmed COVID-19 cases and 100 negative controls were evaluated to determine the diagnostic performance of the isothermal methods. Results Our investigation revealed equally promising diagnostic accuracy of the methods with a sensitivity of 76.32% (95% CI: 65.18%-85.32%) when the target genes were RdRP and ORF1ab for RT-RPA and RT-RAA, respectively, while the combination of N and RdRP in RT-RPA augmenting the accuracy of the assay at a sensitivity of 85.53% (95% CI: 75.58% -92.55%). Furthermore, high specificity was observed for each of the methods ranged 94.00%-98.00%(95% CI: 87.40-9.76%). Conclusion Considering the diagnostic accuracies, both RT-RPA and RT-RAA assays appear suitable for point-of-need deployment towards detection of the pathogen, understanding its epidemiology, case management, and curbing the transmission.

 Point-of-need diagnostics are prerequisite to harness the spread of SARS-CoV-2  Recombinase-based assays rapidly detect COVID-19 in clinical samples  Both isothermal amplification methods show promising diagnostic efficiency  Incorporation of the techniques in "suitcase lab" may facilitate remote deployment

The unprecedented havoc driven by SARS-CoV-2 pandemic has brought tremendous threat to millions of lives and disrupted the global economy as well (Chih-Cheng Lai et al., 2020) . To date, more than four million deaths have been attributed to COVID-19 worldwide, along with an uncountable degree of morbidity (JHU 2021) . Since the discovery in Wuhan city, China of SARS-CoV-2 as the 7 th member of Corona virus family capable of causing human disease, this airborne virus has devastated, and continues to devastate, millions of lives and livelihoods through active and passive ongoing transmission (Tao Wua et al.,2020) . COVID-19 typically manifests as general, flu-like symptoms including fever, cough, fatigue, dyspnea, and gastrointestinal issues (Chen et al., 2020; Huang et al., 2020) . Owing to the overlap of symptoms with other viral infections, early-stage diagnosis of SARS-CoV-2 infection is problematic (Xue et al., 2020) .Further, no 100% effective therapeutic or preventive intervention has yet to be devised, and isolation of the infected individual is the mainstay to curb the transmission of this enigmatic pathogen (Lotfi et al., 2020) . Lockdown fatigue, and the urgent need for continued income to provide the most basic needs, is pressuring this control measure (and cruelly having the greatest impact among the poorest populations that are most at risk).

Therefore, an accurate and rapid diagnostic method that can be applied in resource poorsettings is highly desired for controlling the spread of the virus/disease and directing of treatment to infected individuals.

A handful of direct techniques, including virus isolation, plaque assay, electron microscopy (EM) and Immuno-EM are available for diagnosis of SARS-Cov-2 infection/ COVID-19. However, considering the superior sensitivity, specificity and high-throughput capacity of real-time reverse transcriptase PCR (real-time RT-PCR), this method has become the gold standard for detection (Hemida, 2021) . Moreover, the quantitative ability of the method has also been exploited for prognosis (Ulinici et al., 2021) . Despite promising diagnostic efficacy, the necessity of a highly qualified laboratory, trained personnel and expensive reagents limits the application of this technique at decentralized facilities. This is a critical gap in most developing countries. To overcome such challenges, many antigen/antibody tests for COVID-19 have been developed and validated. These tests are being very frequently used globally, and especially in LMIC settings. Among them, few antigen-based tests including Lumipulse G, LuminraDx and Standard Q nasal showed promising diagnostic efficacy with sensitivity >80% and specificity >95% (PLoS Med 18(8): e1003735). However, most of the antigen and antibody-based tests do not qualify for the desired accuracy (Deeks et al., 2020) . Consequently, there has been a pressing need for a diagnostic tool that could be performed at decentralized facilities without decreasing accuracy and reliability relative to real time RT-PCR tests.

With the consistent demand for an accurate, rapid, less expensive, and easy-to-operate diagnostic tools, isothermal amplification methods such as loop-mediated isothermal amplification (LAMP), CRISPR-based fluorescent application, and Nicking enzyme-assisted reaction (NEAR) have been exploited to detect SARS-COV-2 (James and Alwneh, 2020). These methods require neither thermostable enzymes nor expensive equipment. Notably, a handful of reports have diagnosed COVID-19 through LAMP, and ten RT-LAMP tests have already been approved by Federal Drug Administration (FDA) for emergency use (FDA 2021) . Recently, recombinase polymerase amplification (RPA) assays have emerged as another promising alternative to real-time PCR for the diagnosis of infectious diseases (A and J, 2015; Macdonald et al., 2018; P et al., 2021) . The RPA method has multifarious advantages over other isothermal amplification technologies, including LAMP, such as RT-RPA is comparatively rapid (10-15 mins), requires simple equipment, and easy to operate at ambient temperature (37-42 °C) (Qian et al., 2020) .

Discerning the versatile advantages of reverse transcription (RT)-RPA assay, several creative applications of RT-RPA assays have been reported for the detection of coronaviruses such as MERS-CoV and bovine coronavirus (BCoV) (Behrmann et al., 2020) . Further, the method has been incorporated into a "suitcase laboratory" for point-of-care diagnosis of H7N9 avian influenza virus, Ebola virus, and visceral leishmaniasis (VL), each of which has demonstrated the great potential of this isothermal technology as a diagnostic tool for use in rapidly evolving and resource constrained outbreak situations Mondal et al., 2016; O et al., 2015) .In parallel to other isothermal technologies, RT-RPA have been explored in several studies for diagnosis of SARS-CoV-2 infection (Behrmann et al., 2020; Nassir et al., 2020; Subsoontorn et al., 2020; el Wahed et al., 2021) . Recently, another recombinase-based assay named reverse transcription recombinase aided assay (RT-RAA) has been developed to detect infectious pathogens (Tao Wua et al., 2020) and the diagnostic efficacy of the assay to detect SARS-CoV-2 was well validated in a multi-center study .

Both RT-RPA and RT-RAA methods are isothermal amplification based in which the double stranded DNA denaturation and strand invasion is accomplished by a cocktail of recombinase enzymes, single-stranded binding proteins, and DNA polymerases. The only difference between the methods is the source of recombinase where the former and later use phage derived and bacteria/fungi derived recombinase, respectively (Tao Wua et al., 2020) . Therefore, considering the multifarious advantages of the isothermal methods, in the current study, both RT-RPA targeting E, RdRP and N genes and RT-RAA amplifying ORF1ab methods were evaluated for their ability to diagnosis of SARS-CoV-2 infection. The positive outcome of the study will facilitate the use of this rapid and accurate diagnostic tool at decentralized facilities such as community clinics, especially in the low-and middle-income countries (LIMCs) including Bangladesh.

A diagnostic evaluation study, where a case-control design was followed to evaluate the diagnostic efficiency of both RT-RPA and RT-RAA, was performed. The study was conducted at both the Virology laboratory and Emerging infections and Parasitology laboratory in icddr,b

following IRB approval (PR-20043) . For the study purpose, archived RNA samples were used to evaluate assay performance. Following RNA isolation from the clinical samples (nasopharyngeal swab), real-time RT-PCR was performed at Virology laboratory and then RNA samples were icddr,b for laboratory investigation to detect COVID-19 through RT-PCR. The samples were collected from patients irrespective of age groups. A total of 76 suspected COVID-19 cases were confirmed through real-time RT-PCR and 100 negative control samples were investigated to directly compare isothermal assays. Samples having a Ct value ≤ 37 were considered as positive in RT-PCR. A random code was generated by the study investigator for each sample to ensure that the laboratory personnel were blinded of the classification or type of the sample while performing the assays.

The operational definitions for the study participants from whom the clinical samples were collected are defined below:

The suspected COVID-19 cases were defined in a manner consistent with the WHO guideline, such as (a) A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset, OR (b) A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case in the last 14 days prior to symptom onset; OR (c) A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.

A suspected COVID-19 case with a positive real time RT-PCR test was considered as confirmed COVID-19 case. 

The RT-RPA assays for E, RdRP and N genes were performed according to the method described 

The RT-RAA assay was performed according to the manufacturer's instruction (Jiangsu Qitian Bio-Tech Co. Ltd., China). The assay has been described elsewhere by Wang J et al . The commercial kit for detection of SARS-CoV-2 was a design-locked single tube containing lyophilized primer/probe and enzymes to perform single reaction. At first, 40 µL buffer VII and 4 µL of nuclease-free water was added to each reaction unit tube with a pipette, and 5 µL magnesium acetate I solution was added to the inside of the reaction tube cover.

Subsequently, 1 µL of extracted nucleic acid or 1 µL negative/positive control was added and the tube was closed, and mixed properly. After mixing, the tube was briefly centrifuged and transferred immediately into the T8 (Axxin, Fairfield, Australia) isothermal fluorescence reader.

The reaction temperature was set at 39 °C for 15minutes, and a mixing step was performed after 230 s. The time of each sample to reach the threshold (TT) was measured in real time by the fluorescence signal detector.

Standard statistical methods including contingency tests and Binomial confidence intervals were performed to determine the sensitivity and specificity of the assays with 95% CI.

Parametric and non-parametric tests were performed based on the distribution of data. 

Among the 76 confirmed COVID-19 patients, a total of 63 were found to be positive through RT-RPA when the target gene was N (Table 1) . Although a small decline in the percent sensitivity of the method was observed when the target gene was RdRP, the combination of the target genes augmented the overall sensitivity of RT-RPA assay to 85.53% (95% CI: 75.58% -92.55%) ( Table   1 ). RT-RPA and RT-RAA showed equal sensitivity of 76.32% (95% CI: 65.18%-85.32%) when the target for the former was RdRP and ORF1ab for the latter. Although, all of the 76 samples were positive for both the RdRP and the N gene in real-time RT-PCR, sensitivity for both of the isothermal methods varied across the Ct values for each target gene (Table 2) . It is worth noting, however, in real-time RT-PCR the Ct values were also disparate between the targets.

Similarly, the sensitivity for each of the methods was found to vary for each of the target genes. respectively. A small decline in specificity of 94.00% (95% CI: 87.40%-97.77%) was observed when the aforementioned targets were combined for RT-RPA assay. Like RT-RPA, increased specificity of 97.00% (95% CI: 91.48%-99.38%) was found for RT-RAA. The ROC analysis substantiated the higher accuracy (AUC=0.897) of RT-RPA when the N and RdRP genes were combined (Fig-1) (Table-4) . Again, RdRP and ORF1ab targeted RT-RPA and RT-RAA methods respectively showed parallel diagnostic accuracy. As the E target is specific for all betacorona viruses (SARS, MARS, SARS-CoV-2 etc.) and the target gave high number of false positives (supplementary file #1), therefore, the RT-RPA assay targeting the E gene was excluded from the analysis.

Around two-thirds of the COVID-19 samples (68.7%) were positive by each of the methods when assay outcome of the target genes was independent to each other (Fig 2) . When presented as a Venn diagram, the high degree of overlapping positives between RdRP-RPA and ORF1ab-RAA is readily observed. The higher Kappa coefficient (k=0.836) between the aforementioned methods further bolstered their excellent agreement (Table 3 ). As expected, N-RPA showed good agreement with both RdRP-RPA and ORF1ab-RAA, with kappa vales of 0.755 and 0.719, respectively. Furthermore, a good agreement (k=0662) was observed between the RT-RAA and RT-RPA assay when the N and RdRP targets were combined (Table 3) .

In the absence of any magic bullet against COVID-19, containment of SARS-CoV-2 infections has been the cornerstone for disruption of transmission. Taking into account the previous successes, the three "T" moto (Test, Trace, Treat) has been considered indispensable towards acclimatizing with the new normal era and alleviating the crippling impact on the global economy by diminishing virus spread (Griffin, 2020; Ng, 2020; Zheng et al., 2021) . In this regard, the democratization of COVID-19 testing facilities is still a distant and potentially unattainable goal in low-resource settings because of the lack of universal operating procedures, as well as absence of harmonization and implementation of truly widely available PCR-based diagnostic assays (Kevadiya et al., 2021) . With the advent of isothermal amplification-based point-of-need assays, however, accessibility to diagnosis and faster screening, while maintaining the optimal diagnostic efficacy, is no longer a dream to fight against the pandemic (James and Alwneh, 2020).

Critically, unlike RT-PCR strategies, Isothermal amplification technology with reduced turnaround time require neither professional expertise nor expensive infrastructure and consequently, the technology has the potential to be deployed at the community level. Thus, transfer of samples to a centralized laboratory is not required and the longer execution period associated with the standard COVID-19 real-time RT-PCR test disappears (Subsoontorn et al., 2020) . Considering such a multitude of technical and practical advantages, the overarching goal of our study was to evaluate both RT-RPA and RT-RAA assays as emerging isothermal techniques amenable to resource-limited settings for detection of SARS-CoV-2. Both of the methods showed moderate sensitivity compared to the previous studies, however, while their 20 specificities were comparable (el Wahed et al., 2021; Wang et al., 2020; Xue et al., 2020) . The deviations in diagnostic efficiencies of the tests can be attributed to the sample type, sample quality/quantity, different settings, variable patient cohort and operator. The earlier study performed by Ahmed et al included only 36 samples to evaluate the clinical efficiency of RPA assay whereas 176 samples (76 cases, 100 controls) were under investigation in the current study (el Wahed et al., 2021) . Moreover, the various types of clinical samples used in the study performed by Wang et al. might be responsible for elevated sensitivity of RT-RAA assay . On the other hand, only nasopharyngeal swab samples were used to determine the clinical efficiency of RT-RAA assay in the current study. It is noteworthy, however, that in the previous multicenter study, 62.5% of the swab samples were found to be positive for SARS-CoV-2by RT-RAA test . In the current study, both of the isothermal methods detected most of the samples at Ct values less than 30 in real-time RT-PCR. A recent review by Francois et al showed that the infected individuals with10 6 viral particles/mL are contagiousthe detection limit of the Nucleic Acid Amplification-based methods varies between 10 5 to 10 3 viral particles/mL for clinical samples (Berthiaume, 2021) . Such infected individuals with high CT values are therefore less likely to transmit the virus, and the isothermal techniques detected most of the likely super spreaders. Even without this consideration, both of the tests evaluated achieved the qualification of a useful test by the estimation of sensitivity + specificity (1.5 value), as per the diagnostic test quality proposed by Power et al (Power et al., 2013) .

To the best of our knowledge, this is the first study to directly compare RT-RPA and RT-RAA towards the detection of SARS-CoV-2 in the clinical samples. The major limitations of this study include the use of archived samples and the use of similar type of samples, both of which might influence the true clinical efficiency of the tests. However, we used random samples spanning a range of RT-PCR Ct values with variable viral loads to more robustly assess the efficiency of each test. Furthermore, we used several aliquots of the archived RNA samples to avoid the introduction of freeze-thaw as an impacting variable. Further, the laboratory personnels were blinded to the type of the samples they were evaluating to nullify any operator bias. Finally, apart from the technical aspects, the assay has a limitation in terms of throughput as the portable device can detect eight samples in a single run, however, the developed capacity would be adaptable at resource limited settings to detect other pathogens as well when the pandemic is over.

Considering the current need, the diagnostic efficiencies and feasibility to perform at resourceconstrained settings, both of the isothermal methods demonstrate promise for application as a point-of-need test for the diagnosis of SARS-CoV-2 infection/COVID-19. The RdRP targeted RT-RPA and ORF1ab targeted RT-RAA appear sufficient to specifically detect SARS-CoV-2, and their use would reduce the operational cost. Moreover, the earlier studies confer the detection of the virus through ORF1ab, where both RdRP and ORF1ab flank same region of the genome of SARS-CoV-2 (Corman et al., 2020; el Wahed et al., 2021; Wang et al., 2020) . This also explains the similar diagnostic efficiency or excellent agreement of the methods, while using the aforementioned targets for two different tests. The technical advantages of the RT-RAA are its simple pipetting scheme and the availability of lyophilized all-in-one primer in pellet, which contains the RT, RAA enzyme and protein as well as the SARS-CoV-2 oligonucleotide. Recently, coupling of the methods with CRISPR Cas9/12a has been investigated to develop lateral flow device towards further facilitating point-of-care detection (Sun et al., 2021; Xiong et al., 2021;  prior to large-scale application.

In the last decade, the application of isothermal amplification technologies have been advancing, with recombinase-based isothermal assays contributing around 10% of the global isothermal amplification technology market Since the recombinase-based both RT-RAA and RT-RPA assays are feasible to perform at pointof-need settings, the findings of this study could facilitate the use of these isothermal methods in large scale and in a broad array of settings. Finally, incorporation into the "suitcase lab"

format, along with a rapid nucleic acid extraction technique, would augment the utility of the tests by allowing deployment in the decentralized facilities (rural community clinics, shopping and travel hubs, airports etc.) to combat the outbreak situations.

This study was awarded by the Swedish International Development Cooperation Agency (Sida),

Sweden and the award no is GR-01455. The authors alone are responsible for the views expressed in this manuscript and the funding sources had no role in the study design, collection, analysis and interpretation of the data, preparation of the manuscript, or the decision to submit for publication. 

Diagnostics-in-a-Suitcase: Development of a portable and rapid assay for the detection of the emerging avian influenza A (H7N9) virus

Recombinase polymerase amplification: Emergence as a critical molecular technology for rapid, low-resource diagnostics

Rapid Detection of SARS-CoV-2 by Low Volume Real-Time Single Tube Reverse Transcription Recombinase Polymerase Amplification Using an Exo Probe with an Internally Linked Quencher (Exo-IQ)

COVID-19 Testing: Frequency Wins over Sensitivity in Control of Disease Transmission

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Detection of 2019 -nCoV by RT-PCR

Antibody tests for identification of current and past infection with SARS-CoV-2

Covid-19: Test and trace programmes are important but no silver bullet, say scientists

The next-generation coronavirus diagnostic techniques with particular emphasis on the SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19 infection diagnosis: Potential impact of isothermal amplification technology to reduce community transmission of SARS-CoV-2

Diagnostics for SARS-CoV-2 infections

Review: a comprehensive summary of a decade development of the recombinase polymerase amplification

COVID-19: Transmission, prevention, and potential therapeutic opportunities

Review: a comprehensive summary of a decade development of the recombinase polymerase amplifi cation Analyst CRITICAL REVIEW Review: a comprehensive summary of a decade development of the recombinase polymerase amplification

Mobile suitcase laboratory for rapid detection of Leishmania donovani using recombinase polymerase amplification assay

RPA-BASED METHOD FOR THE DETECTION OF SARS-COV2

Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore

Development and deployment of a rapid recombinase polymerase amplification Ebola virus detection assay in Guinea in 2015

Single-Blinded, Phase 2 Study to Evaluate a Point-of-Need System for Rapid Detection of Leishmaniasis and Its Implementation in Endemic Settings

Principles for high-quality, high-value testing

An enhanced isothermal amplification assay for viral detection

The diagnostic accuracy of isothermal nucleic acid point-of-care tests for human coronaviruses: A systematic review and meta-analysis

One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a

Bin Wua FZ, Baoli Zhua, b LC. A reverse-transcription recombinase-aided amplification assay for the rapid detection of N gene of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)

Diagnostic and Prognostic Tests for COVID-19: A Comprehensive Review

Suitcase Lab for Rapid Detection of SARS-CoV-2 Based on Recombinase Polymerase Amplification Assay

Multiple-centre clinical evaluation of an ultrafast single-tube assay for SARS-CoV-2 RNA

Simultaneous Dual-Gene Diagnosis of SARS-CoV-2 Based on CRISPR/Cas9-Mediated Lateral Flow Assay

Reverse-Transcription Recombinase-Aided Amplification Assay for Rapid Detection of the

Reverse transcription recombinase polymerase amplification coupled with CRISPR-Cas12a for facile and highly sensitive colorimetric SARS-CoV-2 detection

Reverse Transcription Recombinase-Aided Amplification Assay With Lateral Flow Dipstick Assay for Rapid Detection

We are grateful to all of the participants for their valuable participation in this study. The authors are grateful to core donors which provide unrestricted support to icddr,b. Current 

The authors declare that they have no Conflict of Interest.The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Research, Bangladesh (icddr,b) Institutional Review Board (IRB) and ethical review committee (ERC), research protocol number PR-20043. The authors confirm that the ethical policies of the journal, as noted in the journal guidelines, have been adhered to.